Thursday, April 8, 2021 Daily Archives

Catalent: ‘Dedicated Moderna line frees space for our non-COVID customers’

by

Catalent has dedicated a high-speed vial filling line to Moderna at its site in Indiana, which it says will free up space for its non-COVID related customers.  The high-speed vial filling line expands upon an agreement inked between the two firms last June, and provides Moderna with a dedicated fill-finish service through to June 2023. It will initially be used to manufacture Moderna’s COVID-19 vaccine, approved by the US FDA under an emergency use authorization (EUA) last December, though there is potential for it to produce other clinical products in the firm’s pipeline. According to the…

April 8, 2021

CyanVac selects Exothera to make intranasal COVID-19 vaccine

by

CyanVac has partnered with CDMO Exothera to develop and manufacture its intranasal COVID-19 vaccine candidate CVXGA1 using the scale-X platform. Georgia, US-based vaccine developer, CyanVac has selected contract development manufacturing organization (CDMO) Exothera to advance development of a manufacturing process for its COVID-19 vaccine candidate that is administered intranasally as a single dose to prevent SARS-CoV-2 infection. “We have been working on intranasal vaccines for over 20 years,†Biao He, CEO and founder of CyanVac told BioProcess Insider. “The viral vector…

April 8, 2021

TCR2 leases ex-Autolus plant in pivot away from CDMO reliance

by

A lack of control when relying on third-party manufacturers has been a learning lesson for many cell therapy firms says TCR2 Therapeutics as it leases an 85,000 square-foot plant in Rockville, Maryland. T-cell therapy firm TCR2 Therapeutics has entered a 15-year lease agreement for the facility at 9950 Medical Center Drive, Rockville, Maryland for a price of $39.78 per square foot, beginning July 1. According to chief scientific officer Robert Hofmeister, the facility will help expand supply for clinical trials and potential…

April 8, 2021